Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia

Affiliations

• ¹ Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
• ² Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, DC, USA.
• ³ Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
• ⁴ Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN, USA.
• ⁵ The Ohio State University College of Medicine, Columbus, OH, USA.
• ⁶ University of Virginia, Charlottesville, VA, USA.
• ⁷ Bio-Rad Laboratories, Pleasanton, CA, USA.
• ⁸ Sylvester Comprehensive Cancer Center, Miami, FL, USA.
• ⁹ Mayo Clinic, Rochester, MN, USA.
• ¹⁰ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹¹ Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.
• ¹² Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. laura.dillon2@nih.gov.
• ¹³ Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, DC, USA. hourigan@vt.edu.